Reduced Postprandial Concentrations of Intact Biologically Active Glucagon-Like Peptide 1 in Type 2 Diabetic Patients

Diabetes - Tập 50 Số 3 - Trang 609-613 - 2001
Tina Vilsbøll1,2, Thure Krarup1, Carolyn F. Deacon2, Sten Madsbad3, Jens J. Holst2
1Department of Internal Medicine F, Gentofte Hospital
2Department of Medical Physiology, the Panum Institute
3Department of Endocrinology, Hvidovre Hospital, University of Copenhagen, Copenhagen, Denmark

Tóm tắt

Incretin hormones importantly enhance postprandial insulin secretion but are rapidly degraded to inactive metabolites by ubiquitous dipeptidyl peptidase IV. The concentrations of the intact biologically active hormones remain largely unknown. Using newly developed assays for intact glucagon-like peptide (GLP)-1 and glucose-dependent insulinotropic polypeptide (GIP), we measured plasma concentrations after a mixed breakfast meal (566 kcal) in 12 type 2 diabetic patients (age 57 years [range 49–67], BMI 31 kg/m2 [27–38], and HbA1c 9.2% [7.0–12.5]) and 12 matched healthy subjects. The patients had fasting hyperglycemia (10.7 mmol/l [8.0–14.8]) increasing to 14.6 mmol/l (11.5–21.5) 75 min after meal ingestion. Fasting levels of insulin and C-peptide were similar to those of the healthy subjects, but the postprandial responses were reduced and delayed. Fasting levels and meal responses were similar between patients and healthy subjects for total GIP (intact + metabolite) as well as intact GIP, except for a small decrease in the patients at 120 min; integrated areas for intact hormone (area under the curve [AUC]INT) averaged 52 ± 4% (for patients) versus 56 ± 3% (for control subjects) of total hormone AUC (AUCTOT). AUCINT for GLP-1 averaged 48 ± 2% (for patients) versus 51 ± 5% (for control subjects) of AUCTOT. AUCTOT for GLP-1 as well as AUCINT tended to be reduced in the patients (P = 0.2 and 0.07, respectively); but the profile of the intact GLP-1 response was characterized by a small early rise (30–45 min) and a significantly reduced late phase (75–150 min) (P < 0.02). The measurement of intact incretin hormones revealed that total as well as intact GIP responses were minimally decreased in patients with type 2 diabetes, whereas the late intact GLP-1 response was strongly reduced, supporting the hypothesis that an impaired function of GLP-1 as a transmitter in the enteroinsular axis contributes to the inappropriate insulin secretion in type 2 diabetes.

Từ khóa


Tài liệu tham khảo

Creutzfeldt W, Nauck M: Gut hormones and diabetes mellitus. Diabetes Metab Rev 8:149–177, 1992

Scrocchi LA, Brown TJ, MaClusky N, Brubaker PL, Auerbach AB, Joyner AL, Drucker DJ: Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 2:1254–1258, 1996

Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W: Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7–36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 76:912–917, 1993

Deacon CF, Nauck M, Meier J, Hücking K, Holst JJ: Degradation of endogenous and exogenous gastric inhibitory polypeptide (GIP) in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 85:3575–3581, 2000

Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ: Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44:1126–1131, 1995

Pederson RA, Kieffer TJ, Pauly R, Kofod H, Kwong J, McIntosh CH: The enteroinsular axis in dipeptidyl peptidase IV-negative rats. Metabolism 45:1335–1341, 1996

Mentlein R: Dipeptidyl-peptidase IV (CD26): role in the inactivation of regulatory peptides. Regul Pept 85:9–24, 1999

Brown JC, Dryburgh JR, Ross SA, Dupre J: Identification and actions of gastric inhibitory polypeptide. Recent Prog Horm Res 31:487–532, 1975

Weir GC, Mojsov S, Hendrick GK, Habener JF: Glucagonlike peptide I (7–37) actions on endocrine pancreas. Diabetes 38:338–342, 1989

Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JJ: Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol 271:E458–E464, 1996

Nauck M, Stockmann F, Ebert R, Creutzfeldt W: Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29:46–52, 1986

Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183–1197, 1997

Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. I. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539–553, 1998

Heding LG: Radioimmunological determination of human C-peptide in serum. Diabetologia 11:541–548, 1975

Faber OK, Binder C, Markussen J, Heding LG, Naithani VK, Kuzuya H, Blix P, Horwitz DL, Rubenstein AH: Characterization of seven C-peptide antisera. Diabetes 27 (Suppl. 1):170–177, 1978

Krarup T, Madsbad S, Moody AJ, Regeur L, Faber OK, Holst JJ, Sestoft L: Diminished immunoreactive gastric inhibitory polypeptide response to a meal in newly diagnosed type I (insulin-dependent) diabetics. J Clin Endocrinol Metab 56:1306–1312, 1983

Krarup T, Holst JJ: The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera. Regul Pept 9:35–46, 1984

Dyberg T, Kofod H: Synthetic peptides as antigen. In Animal Virus Pathogenesis: A Practical Approach . Oldstone MBA, Ed. Oxford, IRL Press, 1990, p. 163–171

Gutniak MK, Larsson H, Heiber SJ, Juneskans OT, Holst JJ, Ahren B: Potential therapeutic levels of glucagon-like peptide I achieved in humans by a buccal tablet. Diabetes Care 19:843–848, 1996

Holst JJ, Bersani M, Johnsen AH, Kofod H, Hartmann B, Orskov C: Proglucagon processing in porcine and human pancreas. J Biol Chem 269:18827–18833, 1994

Hansen L, Deacon CF, Orskov C, Holst JJ: Glucagon-like peptide-1-(7–36)amide is transformed to glucagon-like peptide-1-(9–36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 140:5356–5363, 1999

Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ: Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43:535–539, 1994

Jornvall H, Carlquist M, Kwauk S, Otte SC, McIntosh CH, Brown JC, Mutt V: Amino acid sequence and heterogeneity of gastric inhibitory polypeptide (GIP). FEBS Lett 123:205–210, 1981

Toft-Nielsen M, Damholt M, Hilsted J, Hughes TE, Krarup T, Madsbad S, Holst J: GLP-1 secretion is decreased in NIDDM patients compared to matched control subjects with normal glucose tolerance (Abstract). Diabetologia 143:A40, 1999

Kjems LL, Volund AA, Madsbad S: The effect of exogenous GLP-1 on the glucose mediated insulin secretion: a dose-response study in patients with type 2 diabetes mellitus and control subjects (Abstract). Diabetologia 142:A39, 1999

Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W: Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91:301–307, 1993

Vaag AA, Holst JJ, Volund A, Beck NH: Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM): evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins. Eur J Endocrinol 135:425–432, 1996

Nyholm B, Walker M, Gravholt CH, Shearing PA, Sturis J, Alberti KG, Holst JJ, Schmitz O: Twenty-four-hour insulin secretion rates, circulating concentrations of fuel substrates and gut incretin hormones in healthy offspring of type II (non-insulin-dependent) diabetic parents: evidence of several aberrations. Diabetologia 42:1314–1323, 1999

Kieffer TJ, Habener JF: The glucagon-like peptides. Endocr Rev 20:876–913, 1999

Orskov C, Jeppesen J, Madsbad S, Holst JJ: Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J Clin Invest 87:415–423, 1991

Deacon CF, Johnsen AH, Holst JJ: Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80:952–957, 1995

Thông tin
Thông tin xuất bản

Diabetes

Tập 50 Số 3

609-613

Thông tin tác giả